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CASE REPORT
JC virus (JCV) is a double-stranded circular deoxy-
ribonucleic acid (DNA) virus belonging to the
family Papovaviridae and genus Polyomavirus.1
It has an extremely limited host range and can
only cause productive infection in humans.2 JCV
is widespread in the human population. Serum
antibody to JCV could be detected in up to 80%
of people beyond late childhood.3 It is postu-
lated that a transient viremia period may de-
velop following primary infection, and the virus
is transported to the kidney where it resides indefi-
nitely.4 Although the virus often remains inactive,
in immunocompromised conditions it may be
reactivated and result in viruria,5,6 chronic neuro-
logic diseases,7,8 or a fatal demyelinating brain
disease, namely progressive multifocal leukoen-
cephalopathy (PML).3,4,8
Being first isolated from the brain tissue of 
a PML victim, JCV was named in 1971 after the ini-
tials of that patient.9 Along with the University of
Wisconsin (Madison) where it was identified,
the isolated strain was designated as prototype
Mad-1.1 The Mad-1 strain differs from the latent
virus that resides in the kidney (archetype) in the
regulatory regions (RR) of the viral genome, with
tandem repeats instead of a single unit.2 Other
prototype-like JCV variants with tandem repeats
were subsequently isolated from the brain tissue
of PML patients.10 The particular RR DNA se-
quences of the prototype and its variant strains
are thought to be responsible for virulence and
specific neurotropism.11
PML is a relentless demyelinating disorder
due to lytic infection of oligodendrocytes by JCV.
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Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating brain disease caused by JC
virus (JCV). Genomic analysis of viral isolates in these cases often shows prototype-like JCV and its variants,
which is a virulent strain compared to the latent archetype virions mostly found in the kidney. Here, we re-
port a 57-year-old man who suffered from a subacute course of cognitive impairment and multiple neurologic
deficits. Neuroimaging, pathology, and virology studies showed multifocal leukoencephalopathy and the
presence of JCV deoxyribonucleic acid in the cerebrospinal fluid. The prototype type 1 (Mad-1) strain of
JCV was identified on viral genotyping obtained from brain tissue. No immune deficits were found. He re-
sponded poorly to α-interferon and antiviral treatment. This case suggests that lack of immune deficiency
cannot exclude the possibility of PML as a cause of subacute leukoencephalopathy. Accumulated data with
respect to the disease course, pathologic feature, and viral genomic subtyping may pave the way for future
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PML in an immunocompetent patient
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Clinically, patients may present with various
neurologic deficits resulting from multifocal brain
involvement. PML was once thought to be a rare
disease until increasing case numbers were encoun-
tered in patients with acquired immunodefi-
ciency syndrome (AIDS), organ transplantation,
and immunocompromised status.2,8 In Taiwan,
the definite diagnosis of PML has not been des-
cribed and this is probably due to difficulty in
virus isolation and lack of availability of neces-
sary diagnostic tools in most hospitals. Here, we
report a confirmed case of PML including the
clinical course, typical neuroimaging findings,
and pathologic features. Compatible virus DNA
material was detected from the cerebrospinal fluid
(CSF), and genomic sequencing revealed JCV pro-
totype Mad-1 in brain tissue.
Case Report
A 57-year-old right-handed professional driver
had no history of substance abuse or toxin expo-
sure. He had an 8-year history of hypertension and
hyperuricemia, which were under good medical
control. Three months prior to admission, he suf-
fered a generalized seizure but did not seek medical
attention. Due to subacute onset behavior disorder
and speech problems, he was admitted for further
investigation. On admission, vital signs and physi-
cal examination were normal. Neurologic exami-
nation disclosed poor attention, dysphasia, visual
agnosia, and generalized hyperreflexia. Laboratory
studies including a complete blood cell count, bio-
chemistry, and adrenal and thyroid hormone were
all normal. Serologic tests disclosed a carrier state
of hepatitis B. Serum IgMs to cytomegalovirus,
herpes simplex virus types 1 and 2, and toxo-
plasma were all negative. Tests of antibodies to
the human immunodeficiency virus 1+2, as well
as reagin plasma response and treponema pal-
lidum hemagglutination were all negative. Serial
immunologic survey showed C3 142 mg%, C4
38.5 mg%, IgG 1530 mg%, IgM 90.4 mg%, and no
paraprotein in the serum or CSF. Results of mononu-
clear cell quantitation were as follows: CD3+ 538
cells/μL, CD19+ 132 cells/μL, CD4+ 308 cells/μL,
CD8+ 250 cells/μL, CD4+/CD8+ 1.23, NK 174
cells/μL. Tumor markers including carcinoembry-
onic antigen, carbohydrate antigen (CA) 125, CA
15-3, CA 19-9, and prostate-specific antigen were
not elevated. Cytologic and biochemical analyses
of CSF were within normal limits. Electroence-
phalography demonstrated slowing background
with abundant theta and delta waves, and focal
epileptogenicity in bilateral parieto-occipital areas.
Cranial magnetic resonance imaging (MRI)
showed high intensity lesions in the white matter
of bilateral parieto-occipital lobes on T2-weighted
images and fluid attenuated inversion recovery
pulse sequence (Figure 1A). His consciousness
deteriorated to stupor with limited eye move-
ment, and limb jerks emerged gradually. Despite
advanced laboratory survey, the definite etiology
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Figure 1. (A) T2-weighted fluid attenu-
ated inversion recovery images show
hyperintense lesions without mass 
effect in both parieto-occipital regions,
especially in the periventricular and
subcortical white matter. (B) Follow-up
study 4 weeks later shows significant
expansion in the size of the preexisting 
lesions and the appearance of new 
lesions in bilateral frontal white matter.
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of the brain lesion remained obscure. Thus, leu-
koencephalopathy of undetermined cause was
diagnosed and a stereotactic brain biopsy was
performed to confirm the diagnosis and guide
therapy. Microscopic examination of specimens
taken from the right occipital lobe found no malig-
nant cell or prominent inflammatory response, but
abundant degenerated neurons, atypical astrocytes,
foamy macrophages, and oligodendrocytes with
intranuclear inclusion bodies were observed
(Figure 2A). Immunohistochemical assay using
anti-JCV antibody (Novocastra, Newcastle, UK)
showed positive staining in the oligodendrocytes,
astrocytes, and paravascular cells (Figure 2B and C).
According to the clinical course, characteristic MRI
picture, and specific histopathologic findings, a
clinical diagnosis of PML was established.
For detecting JCV DNA, polymerase chain re-
action (PCR) amplification was performed, using
two different sets of specific primers. Sequences
of the first set (P1: 5′-AAGTCAATATCTATATCA-
GATACA, P2: 5′-AGTTGCTTGCCCATTAGAG) were
based on the conserved region of the major 
capsid protein (VP-1 region) of the JCV genome
extending from base pair (bp) 1646 to 1852.12
The second set of primers applied was JBR1 (5′-
CCTCCACGCCCTTACTACTTCTGAG) and JBR2
(5′-GTGACAGCTGGCGAAGAACCATGGC),
annealing to the constant ends of RR (nucleotide
−45 to −21 and 265 to 289) of the JCV.5,6 The
viral DNAs coding for VP-1 structural protein were
positive in urine and CSF samples (data not
shown). In addition, JCV DNA bands of the non-
coding RR with the expected size of 334 bp were
found in urine, peripheral lymphocytes, CSF, and
brain (Figure 3). To determine the specific geno-
type of JCV in brain tissue, the PCR product of the
RR element was purified and sequenced using the
fmol DNA sequencing kit (Promega, USA), and
shown to be identical to Mad-1.1
The patient remained stuporous with compli-
cations of recurrent nosocomial pulmonary and
urinary tract infections, the development of which
were attributed to his severe neurologic condition.
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Figure 2. Specimen from the stereotactic brain biopsy. 
(A) A paraffin-embedded section stained with hematoxylin
and eosin shows abnormal enlarged astrocytes, degenerated
neurons, and swollen oligodendrocytes with inclusion bodies
(200×). The scale bar represents 100 μm. (B, C) Immuno-
staining with antibodies against JC virus VP1 protein shows
positive staining in the oligodendrocytes, astrocytes, and
paravascular cells, which confirmed the diagnosis of progres-
sive multifocal leukoencephalopathy (600×).
His consciousness improved slightly while on 
recombinant α-2a interferon therapy, but later
deteriorated again despite adding cytosine arabi-
noside (2 mg/kg body weight per day, 5 consecu-
tive days per week for 2 weeks) to his treatment
regimen. Follow-up brain MRI disclosed signifi-
cant expansion of the previous lesions, and the
development of new lesions in bilateral frontal
white matter (Figure 1B). The patient died of severe
pulmonary infection and septic shock 2 months
after admission.
Discussion
JCV often causes asymptomatic infection of the
kidney with intermittent viruria. Archetype JCV is
the most commonly found strain in the kidney but
is seldom discovered in the CNS. The nucleotide
sequence of the RR is believed to play a decisive
role in determining host range, virulence, and cel-
lular tropism.13 Based on the sequence variation in
the RR,14 the most often isolated strains from brain
lesions are prototype Mad-1 and prototype-like
variant with 98-bp tandem repeats, in contrast to
the “archetype” latent strain harboring a single copy
of the 98-bp tandem. In our patient, histologic
examination confirmed demyelinating changes in
association with inclusion bodies within oligo-
dendroglia highly suggestive of a virus-related dis-
ease entity. Molecular studies further demonstrated
that the viral genome was identical to Mad-1, a
virulent strain, which attacks the nervous system.
Clinically, PML often occurs in patients with dis-
orders involving a compromised immune system,
e.g. lymphoproliferative disease, malignancy, pro-
tracted granulomatous disease, organ-transplanted
status, and pandemic AIDS.8 It is believed that
immunosuppression may lead to reactivation or
mutation of latent polyomavirus.8 However, im-
mune insufficiency is not a prerequisite in the
diagnosis of PML. In immunocompetent indi-
viduals15 or those with restored immune func-
tion, PML should also be included in the list of
differential diagnosis once a compatible clinical
course and typical imaging findings are encoun-
tered.13 Immunologic surveys in our patient were
normal except for a borderline CD4+ count. Low
CD4 cell count per se is found in various condi-
tions ranging from viral or bacterial infection,
trauma, dementia, stroke to psychologic stress.
How PML develops in immunocompetent pa-
tients is still unknown. It is possible that viremia
and viral mutation could have occurred during
PML in an immunocompetent patient
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Figure 3. Detection of the JC virus deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR) in the urine, peripheral
lymphocytes, cerebrospinal fluid (CSF), and brain tissue from this progressive multifocal leukoencephalopathy patient.
The PCR products (334 base pair) were amplified using JBR1 (5′-CCTCCACGCCCTTACTACTTCTGAG-3′) and JBR2 
(5′-GTGACAGCTGGCGAAGAACCATGGC-3′) primers and demonstrated after 5% acrylamide gel electrophoresis. M: DNA
size marker; lanes 1–3: urine supernatant 3, 5, 10μL, respectively; lanes 4–6: urine sediment 0.1, 3, 5μL, respectively; lanes
7–9: CSF 3, 5, 10 μL, respectively; lanes 10–12: brain tissue DNA 3, 5, 9 μL, respectively; lanes 13–14: blood DNA 5, 9 μL,
respectively; lane 15: negative control.
an immunosuppressed period (e.g. other infec-
tion or psychologic stress).
In the past, the clinical diagnosis of PML was
often a difficult task. This may have been due to in-
sufficient imaging resolution,16 failure to perform
needed brain biopsy, and difficulties in the isola-
tion and culture of the virus.17 A definite diagnosis
of PML can now be readily attained by detecting
JCV DNA and antigens in brain lesions using in situ
hybridization or immunohistochemistry.18,19 JCV
DNA can be detected by PCR amplification in the
CSF in 80–92% of biopsy-proven PML cases.20,21
This may facilitate the initial screening, reduce the
need for brain biopsy, and enhance the under-
standing of the molecular details of the virus.
In conclusion, this is the first report of a pathol-
ogy and virology proven PML case in Taiwan. Lack
of immune deficiency cannot exclude the possi-
bility of PML as one of the causes of leukoence-
phalopathy. Molecular studies for initial screening
and final genomic classification of the viral strain
are invaluable for identifying the disease entity.
Although there is still no effective therapy for PML,
the gathered clinical, pathologic, and molecular
information can form the basis of designing ratio-
nal care and treatment for this devastating disease.
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